JP2008521795A5 - - Google Patents

Download PDF

Info

Publication number
JP2008521795A5
JP2008521795A5 JP2007542513A JP2007542513A JP2008521795A5 JP 2008521795 A5 JP2008521795 A5 JP 2008521795A5 JP 2007542513 A JP2007542513 A JP 2007542513A JP 2007542513 A JP2007542513 A JP 2007542513A JP 2008521795 A5 JP2008521795 A5 JP 2008521795A5
Authority
JP
Japan
Prior art keywords
leptin
antagonist
seq
leptin antagonist
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007542513A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008521795A (ja
JP5113526B2 (ja
Filing date
Publication date
Priority claimed from US10/996,607 external-priority patent/US7307142B2/en
Application filed filed Critical
Publication of JP2008521795A publication Critical patent/JP2008521795A/ja
Publication of JP2008521795A5 publication Critical patent/JP2008521795A5/ja
Application granted granted Critical
Publication of JP5113526B2 publication Critical patent/JP5113526B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007542513A 2004-11-26 2005-11-24 レプチン拮抗薬 Expired - Fee Related JP5113526B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/996,607 US7307142B2 (en) 2004-11-26 2004-11-26 Leptin antagonists
US10/996,607 2004-11-26
PCT/IL2005/001250 WO2006056987A2 (en) 2004-11-26 2005-11-24 Leptin antagonists

Publications (3)

Publication Number Publication Date
JP2008521795A JP2008521795A (ja) 2008-06-26
JP2008521795A5 true JP2008521795A5 (enExample) 2009-02-05
JP5113526B2 JP5113526B2 (ja) 2013-01-09

Family

ID=36204374

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007542513A Expired - Fee Related JP5113526B2 (ja) 2004-11-26 2005-11-24 レプチン拮抗薬

Country Status (8)

Country Link
US (1) US7307142B2 (enExample)
EP (1) EP1814986B1 (enExample)
JP (1) JP5113526B2 (enExample)
CN (1) CN101189335B (enExample)
AT (1) ATE498683T1 (enExample)
DE (1) DE602005026432D1 (enExample)
ES (1) ES2363011T3 (enExample)
WO (1) WO2006056987A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
CA2725143A1 (en) * 2008-05-21 2009-11-26 Neurotez, Inc. Methods for treating progressive cognitive disorders related to neurofibrillary tangles
WO2010054017A1 (en) * 2008-11-04 2010-05-14 Nikolaos Tezapsidis Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
WO2010117785A1 (en) * 2009-03-31 2010-10-14 Temple University - Of The Commonwealth System Of Higher Education Leptin antagonist and methods of use
BR112012026718A2 (pt) 2010-04-22 2017-12-19 Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct antagonista de leptina sintético, molécula de dna isolada, composição farmacêutica, método para o tratamento de uma doença ou condição, rato transgênico e método de varredura de uma substância tendo atividade terapêutica para uma doença ou distúrbio.
WO2014024189A1 (en) * 2012-08-06 2014-02-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Pegylated high affinity leptins with increased biological activity
IT1423968B1 (enExample) * 2014-04-28 2016-08-26
US11123461B2 (en) 2015-02-26 2021-09-21 Remodeless Cv Ltd Treatment of ischemia and reperfusion using leptin antagonist
US10926006B2 (en) 2015-02-26 2021-02-23 Remodeless Cv Ltd Drug eluting stent
CA2977607A1 (en) * 2015-02-26 2016-09-01 Jacob Schneiderman Methods and compositions relating to leptin antagonists
CN104829708B (zh) * 2015-05-06 2017-11-28 广东省生物资源应用研究所 一条d螺旋区突变的瘦素活性肽及其编码基因和应用
CN104829707B (zh) * 2015-05-06 2017-12-19 广东省生物资源应用研究所 一条cd环和e螺旋区突变的瘦素活性肽及其编码基因和应用
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
AU2017359439B2 (en) * 2016-11-08 2024-11-28 Regeneron Pharmaceuticals, Inc. Antigen-binding proteins that antagonize leptin receptor
AU2019249273A1 (en) 2018-04-06 2020-10-15 Regeneron Pharmaceuticals, Inc. Methods of treatment using a leptin receptor agonist antibody
MX2021007394A (es) 2018-12-18 2021-07-15 Regeneron Pharma Composiciones y metodos para aumentar el peso corporal y la masa muscular magra mediante el uso de antagonistas contra el receptor de leptina, gdf8 y activina a.
WO2024050285A2 (en) * 2022-08-31 2024-03-07 The Board Of Trustees Of The Leland Stanford Junior University Leptin analogs for treating obesity and weight management

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
WO1997020933A2 (en) * 1995-12-06 1997-06-12 Schering Corporation MUTATIONAL VARIANTS OF MAMMALIAN Ob GENE PROTEINS
US20020160935A1 (en) 2000-03-24 2002-10-31 Smithkline Beecham Plc Use of leptin antagonists for the treatment of diabetes
RU2201249C2 (ru) 1996-09-20 2003-03-27 Хехст Акциенгезелльшафт Применение антагонистов лептина для лечения резистентности к инсулину при диабете ii типа
JP2004532618A (ja) * 2001-02-06 2004-10-28 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 低減された免疫原性を有する修飾されたレプチン

Similar Documents

Publication Publication Date Title
JP2008521795A5 (enExample)
JP2006506942A5 (enExample)
RU2016103067A (ru) Улучшенные аминокислотные последовательности, направленные против респираторно-синцитиального вируса человека (hrsv), и полипептиды, включающие такие последовательности, для профилактики и/или лечения инфекций дыхательных путей
JP2011511753A5 (enExample)
JP2009524429A5 (enExample)
JP2013515055A5 (enExample)
NO20025153D0 (no) FremgangsmÕter og sammensetninger for Õ svekke formering av HIV-1
JP2013515057A5 (enExample)
JP2006512300A5 (enExample)
JP2014510518A5 (enExample)
JP2011502964A5 (enExample)
JP2010529860A5 (enExample)
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
HRP20171694T1 (hr) Novi pripravci i postupci
JP2003533186A5 (enExample)
JP2009533317A5 (enExample)
JP2010513327A5 (enExample)
WO2007018619A3 (en) Chimeric therapeutic agents
WO2008113970A3 (en) Peptides
DE602004027362D1 (de) Zusammensetzungen und verfahren mit dem respiratory syncytial virus untergruppe b stamm 9320
JP2012518669A5 (enExample)
EP1982992A4 (en) HLA BINDING PEPTIDE, PRE-STEP, DNA DOMAGING AND RECOMBINANT VECTOR
JP2008510468A5 (enExample)
JP2019038772A5 (enExample)
DE60234103D1 (de) Kontrolle des wachstums und der reparatur von gastrointestinalgewebe durch gastrokine